AcuCort announces today that the nomination committee for the 2023 annual general meeting has been appointed and consists of the company’s two largest owners.
After consultation with the company’s largest shareholders in terms of votes, as of September 30, 2022, the nomination committee consists of the following members:
- Sarah Fredriksson, appointed by AQILION AB
- Thomas Nestenius, appointed by Zoya Invest AB
The annual general meeting will be held on 4 May 2023 in Lund. The nomination committee’s proposal will be presented in the notice to the annual general meeting and on the company’s website.
For more information, please contact:
The information was submitted for publication, through the agency of the contact person above, on February 13, 2023.
About AcuCort AB (publ)
AcuCort AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. All in all, it strengthens the company’s assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.